{"id":"W3133509869","doi":"10.1056/nejmoa1911149","title":"Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":841,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis","keywords":"Fulvestrant; Oncology; Medicine; Internal medicine; Interim analysis; Cancer; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Metastatic breast cancer; Clinical trial; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002016509,0.0004663757,0.0009815978,0.0003160218,0.0001074732,0.0003411692,0.0002916363,0.000314533,0.001599191],"category_scores_gemma":[0.001045454,0.00008462976,0.001290312,0.0002554279,0.0002540481,0.0002641142,0.0003362611,0.0007671487,0.0001718443],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004513633,"about_ca_system_score_gemma":0.0006198118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002512917,"about_ca_topic_score_gemma":0.0006719169,"domain_scores_codex":[0.9995776,0.0002112611,0.0000240596,0.00005530466,0.00006200193,0.00006980638],"domain_scores_gemma":[0.9995781,0.0001316335,0.0001274356,0.0000387958,0.00002545555,0.00009864355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5498958,0.004977269,0.03258139,0.001265657,0.00309894,0.0002265407,0.0001411531,0.008365161,0.02346944,0.0003751449,0.003428764,0.3721747],"study_design_scores_gemma":[0.1813729,0.5445829,0.2338703,0.000388973,0.006002312,0.001041148,0.00007881624,0.004341404,0.01188462,0.001610814,0.01477291,0.00005282215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837903,0.01193381,0.00095151,0.0004416962,0.0001175825,0.0002794385,0.0005618923,0.00006700816,0.001856563],"genre_scores_gemma":[0.994753,0.002805769,0.0005681951,0.0002518721,0.00009216961,0.0002813188,0.0007857335,0.000007269647,0.0004548273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002016509,"threshold_uncertainty_score":0.01066446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01125536094792389,"score_gpt":0.2819309661319838,"score_spread":0.2706756051840599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}